43 related articles for article (PubMed ID: 35957951)
1. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
Bilani N; Patel R; Crowley F; Tiersten A
Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
[TBL] [Abstract][Full Text] [Related]
3. YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation.
Park I; Lee Y; Kim JH; Bae SJ; Ahn SG; Jeong J; Cha YJ
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894401
[TBL] [Abstract][Full Text] [Related]
4. The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.
Jackisch C; Anastasiadou L; Aulmann S; Argyriadis A; Möbus V; Solbach C; Baier P; Giesecke D; Ackermann S; Schulmeyer E; Gabriel B; Mosch D; Buchen S; Krapfl E; Hurst U; Vescia M; Tesch H; Thill M
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38874685
[TBL] [Abstract][Full Text] [Related]
5. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.
Makower D; Lin J; Xue X; Sparano JA
NPJ Breast Cancer; 2021 Mar; 7(1):20. PubMed ID: 33649322
[TBL] [Abstract][Full Text] [Related]
6. Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.
Shachar SS; Leviov M; Yerushalmi R; Drumea K; Tokar M; Soussan-Gutman L; Bareket-Samish A; Sonnenblick A; Ben-Baruch N; Evron E; Gal-Yam EN; Paluch-Shimon S; Bar-Sela G; Goldvaser H; Stemmer SM
NPJ Breast Cancer; 2023 Sep; 9(1):79. PubMed ID: 37775723
[TBL] [Abstract][Full Text] [Related]
7. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
[TBL] [Abstract][Full Text] [Related]
8. Multigene assays in early breast cancer: Insights from recent phase 3 studies.
Markopoulos C; Hyams DM; Gomez HL; Harries M; Nakamura S; Traina T; Katz A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):656-666. PubMed ID: 31706719
[TBL] [Abstract][Full Text] [Related]
9. Oncotype DX Recurrence Score in premenopausal women.
Zhang S; Fitzsimmons KC; Hurvitz SA
Ther Adv Med Oncol; 2022; 14():17588359221081077. PubMed ID: 35295864
[TBL] [Abstract][Full Text] [Related]
10. Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.
Braun M; Kriegmair A; Szeterlak N; Andrulat A; Schrodi S; Kriner M; Hanusch C; Hamann M; Stoetzer O; Pölcher M
Breast Care (Basel); 2022 Jun; 17(3):288-295. PubMed ID: 35957951
[TBL] [Abstract][Full Text] [Related]
11. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
12. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
Knape N; Park JH; Agala CB; Spanheimer P; Morrow M; Downs-Canner S; Baldwin XL
Ann Surg Oncol; 2023 Feb; 30(2):1042-1050. PubMed ID: 36217063
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
14. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
